Nuclear Imaging and Therapy

,; Veenstra, Emile

doi:10.33612/diss.749428332

Cited by 1 publication

(1 citation statement)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the American Society of Hepatology and the European Society of Hepatology recommendations, dynamic contrast-enhanced CT is one of the standard tests for suspected liver cancer, with a sensitivity and specificity of 71% and 87%, respectively; needle biopsy of liver mass usually fails for the purpose of diagnosis; tumour cells can be seen in the pathological tissue of liver mass injury biopsy; the diagnostic accuracy of tumour diameter >2 cm is greater than that of diameter 1-2 cm and diameter <1 cm [ 29 ]. Dynamic contrast-enhanced CT is sometimes used to evaluate individuals with strong suspicions, but because of its high cost and lack of specificity, it is not recommended for screening due to its high cost and radiation risks [ 30 , 31 ].…”

Section: Reviewmentioning

confidence: 99%

Updates on the Diagnostic Use of Ultrasonography Augmented With Perfluorobutane Contrast in Hepatocellular Carcinoma: A Meta-Analysis

Wally,

Albalawi,

Al Madshush

et al. 2024

Cureus

View full text Add to dashboard Cite

To investigate the diagnostic accuracy of contrast-enhanced ultrasound (CEUS) in the diagnosis of primary hepatocellular carcinoma (HCC), a thorough search was conducted for pertinent literature using PubMed, SCOPUS, Web of Science, Science Direct, and Wiley Library. This was a meta-analysis of diagnostic test accuracy. MetaDiSc 1.4 was used for all analyses and assessed statistical heterogeneity with the I2 index and the chi-square test. The random-effects model was applied where there was considerable heterogeneity. Using the eight elements of the Newcastle-Ottawa Scale (NOS) for cohort and case-control studies, we assessed the quality of the included studies. Our results included nine studies with a total of 2598 patients, and 1607 (61.8%) were males. The pooled overall sensitivity of perfluorobutane with CEUS was 85.6% (95% CI 0.832, -0.878, and P=0.000) and specificity was 91.5% (95% CI 0.899, -0.930, and P=0.000) with significant inter heterogeneity between studies (I2=94.3% and 95.7%), respectively. The pooled positive likelihood ratio was 12.42 (4.59 to 33.61, P=0.000). Our analysis revealed a symmetric summary receiver operating characteristic (SROC) curve and seven of the included studies are near the top left corner of the graph, indicating that this test has a high diagnostic value. The results showed that CEUS augmented with perfluorobutane contrast had good diagnostic accuracy (sensitivity and specificity) for primary HCC. Further real-world data studies are needed to confirm the good diagnosis accuracy of perfluorobutane CEUS in primary HCC.

show abstract

Section: Reviewmentioning

confidence: 99%